Azala

Immunotherapy in Hepatocellular Carcinoma

Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of t...

Deskribapen osoa

Gorde:
Formatua: Online
Hizkuntza:ingelesa
Argitaratua: MDPI - Multidisciplinary Digital Publishing Institute 2023
Gaiak:
cancer immunotherapy
TCGA
mutations
copy number variations
microRNAs
PD-1
PD-L1
hepatocellular carcinoma
predictive factors
immunotherapy
immune checkpoint inhibition
check-point inhibitors
liver disease
outcome
biomarkers
combination immunotherapy
immune-related adverse events (irAEs)
hepatocellular carcinoma (HCC)
alpha fetoprotein response
immune checkpoint inhibitor
unresectable hepatocellular carcinoma
a disintegrin and metalloprotease 9
nivolumab
natural killer
CTLA-4
combination therapy
PD-1 antibody
PD-L1 antibody
anti-VEGF inhibitor
molecular classification
immune phenotype
stem cell marker
oncogenic signal
β-catenin
genetic alteration
liver cancer
effectiveness
safety
HCC
molecular-targeted agent
TACE
tyrosine kinase inhibitor
CD14+ cells
programmed death 1 ligands
translational approaches
combination therapies
therapy resistance
predictive markers
tissue-resident memory CD8 T cells
immune checkpoint blockade
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
Sarrera elektronikoa:ONIX_20230511_9783036566917_39
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

ONIX_20230511_9783036566917_39

Antzeko izenburuak